AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
A triplet did worse than control in first-line kidney cancer.